3 hours Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis Seeking Alpha Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis. Eli Lilly (LLY)
7 hours Driehaus Capital Management LLC Buys 793 Shares of Eli Lilly and Company (NYSE:LLY)MarketBeat
1 day 33,819 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Magnolia Capital Advisors LLCMarketBeat
2 days Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s DiseaseInsider Monkey
2 days Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for YearsThe Motley Fool
4 days BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPOInvestor's Business Daily
1 week Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher TodayThe Motley Fool
2 weeks Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest InInsider Monkey
2 weeks This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly’s Weight-Loss TreatmentsThe Motley Fool
2 weeks This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk’s and Eli Lilly’s Weight Loss TreatmentsThe Motley Fool
2 weeks Drugmakers bet billions that targeted radiation could become the next cancer breakthroughCNBC
2 weeks World’s Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, ModernaYahoo Finance
3 weeks Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right NowYahoo Finance
3 weeks Roche stock is falling after report its Wegovy challenger is causing patients to vomitFortune
3 weeks Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes, Alzheimer’s drugsCNBC
3 weeks Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I’m Not Talking About Zepbound)The Motley Fool
3 weeks Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli LillyThe Motley Fool
3 weeks Jim Cramer Says Eli Lilly and Company (LLY) Has the Biggest Pharmaceutical PotentialInsider Monkey
3 weeks Does Eli Lilly and Company (LLY)’s Financial Performance Make It A Safe Stock To Invest In Now?Insider Monkey
3 weeks This Big Move by Eli Lilly May Solve the Weight Loss Drug Market’s Biggest ProblemYahoo Finance
4 weeks Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha
4 weeks Eli Lilly Just Made Zepbound Even More Appealing. Here’s What Smart Investors Need to Know.The Motley Fool
4 weeks How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia’s Battle With Microsoft, AppleInvestor's Business Daily
4 weeks Eli Lilly Trades Near All-Time High: Check Out The IBD 50, Big Cap 20, Other Top Stock ListsInvestor's Business Daily
4 weeks Novo Nordisk’s Ozempic Shortage Is Worsening. It’s Good News For Eli Lilly Stock.Yahoo Finance
4 weeks Novo Nordisk Says Ozempic Shortage Is Worsening. Why It’s Good News For Eli Lilly.Yahoo Finance
4 weeks Tech market values fall on AI costs and recession fears; Eli Lilly, Berkshire gainYahoo Finance
1 month These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right NowThe Motley Fool
1 month Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your MindThe Motley Fool
1 month Is Eli Lilly Stock a No-Brainer Buy After the Company’s Brilliant Zepbound Move?The Motley Fool
1 month Eli Lilly’s Stock Keeps Looking Better and Better. Here’s the Latest Reason Why.The Motley Fool
1 month Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared HolzYouTube
1 month Eli Lilly says weight-loss drug Zepbound now available in 2.5- and 5-milligram vials at 50% discountMarketWatch
1 month Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supplyYouTube
1 month Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts sayMarketWatch
1 month If You Like Eli Lilly, Then You’ll Love This Little-Known Specialty Manufacturing StockThe Motley Fool